文献速递心脑血管急症重症综合管理与镇静镇痛

SANGUINATE™(聚乙二醇化羧基血红蛋白牛源)改善蛛网膜下腔出血后延迟性脑缺血高危脑区的脑血流

SANGUINATE™ (PEGylated Carboxyhemoglobin Bovine) Improves Cerebral Blood Flow to Vulnerable Brain Regions at Risk of Delayed Cerebral Ischemia After Subarachnoid Hemorrhage.
PubMed 文献 · Neurocrit Care · 2017-01-01
一句话结论在12例SAH后DCI高危患者中,SANGUINATE使易损脑区局部CBF升高16%并降低OEF,但24小时未持续,需重复给药研究。

本研究为安全性及原理验证研究,纳入12例蛛网膜下腔出血后存在延迟性脑缺血风险的病人,给予三个递增剂量(160、240、320 mg/kg)的SANGUINATE。用15O-PET在基线、给药后及24小时评估脑血流和氧摄取分数(OEF)。结果:平均动脉压一过性升高(116±15至127±13 mm Hg,p=0.001),24小时恢复,3例DCI患者停用升压药;输注期间无不良事件。总体CBF未升高(43±8至46±9 ml/100 g/min),最高剂量组有趋势(45±7至51±9,p=0.044);易损区(基线OEF≥0.50)局部CBF显著升高16%并伴OEF下降,但24小时未持续。作者结论认为该药可改善局部CBF,可能改善氧供-需求平衡,需临床研究(可能重复给药)评估能否预防DCI或脑梗死。

要点

  • 在12例SAH后DCI高危患者中,SANGUINATE(160、240、320 mg/kg递增剂量)使易损脑区(基线OEF≥0.50)局部CBF升高16%并降低OEF,但24小时未持续。
  • 给药后平均动脉压一过性由116±15升至127±13 mm Hg(p=0.001),24小时恢复,3例DCI患者因此停用升压药。
  • 总体CBF未升高(43±8至46±9 ml/100 g/min),最高剂量组见趋势(45±7至51±9,p=0.044)。
  • 输注期间无不良事件报告。
  • 作者结论:该药可改善局部CBF、可能改善氧供-需求平衡,需临床研究(可能重复给药)评估能否预防DCI或脑梗死。

适用人群与场景

  • 蛛网膜下腔出血后存在延迟性脑缺血风险的12例患者。
  • 易损脑区定义为基线OEF≥0.50。

诊断标准与关键阈值

  • 易损脑区定义:基线OEF≥0.50。
  • DCI风险为入组条件,原文未给出具体诊断标准。

处置流程与药物剂量

  • SANGUINATE三个递增剂量:160、240、320 mg/kg,原文未写明给药途径、频次或疗程。
  • 15O-PET在基线、SANGUINATE给药后及24小时进行,评估CBF和OEF。

红旗征与不能漏的情况

  • 给药后平均动脉压一过性升高(116±15至127±13 mm Hg,p=0.001),24小时恢复。

研究设计与关键结果

  • 研究类型:安全性及原理验证研究,样本量12例SAH后DCI高危患者,三个递增剂量(160、240、320 mg/kg)。
  • 主要结果:平均动脉压一过性由116±15升至127±13 mm Hg(p=0.001),24小时恢复,3例DCI患者停用升压药;输注期间无不良事件。
  • 总体CBF未升高(43±8至46±9 ml/100 g/min),最高剂量组见趋势(45±7至51±9,p=0.044)。
  • 易损区(基线OEF≥0.50)局部CBF显著升高16%并伴OEF下降,但24小时未持续。

证据类型、等级与局限

  • 证据类型:安全性及原理验证研究(12例)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论:该药可改善局部CBF、可能改善氧供-需求平衡;需临床研究(可能重复给药)评估能否预防DCI或脑梗死。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Delayed cerebral ischemia (DCI) after subarachnoid hemorrhage (SAH) has been linked to focal reductions in cerebral blood flow (CBF) and microvascular impairments in oxygen delivery. Effective therapies that restore flow and oxygen transport to vulnerable brain regions are currently lacking. SANGUINATE is a dual-action carbon monoxide-releasing and hemoglobin-based oxygen transfer agent with efficacy in animal models of focal brain ischemia and tolerability in patients with sickle cell disease.

METHODS: We performed a safety and proof-of-principle study in 12 SAH patients at risk of DCI across three escalating doses (160, 240, and 320 mg/kg). We used 15O-PET (performed at baseline, after SANGUINATE and at 24 h) to evaluate efficacy for improving CBF and restoring flow-metabolism balance (assessed by oxygen extraction fraction [OEF]) to vulnerable regions (defined as baseline OEF ≥ 0.50).

RESULTS: SANGUINATE resulted in a transient rise in mean arterial pressure (116 ± 15-127 ± 13 mm Hg, p = 0.001) that normalized by 24 h and allowed three patients with DCI to be weaned off vasopressors. No adverse events were noted during infusion. Global CBF did not rise (43 ± 8-46 ± 9 ml/100 g/min) although a trend was seen at the highest dose (45 ± 7-51 ± 9, p = 0.044). However, a significant 16% rise in regional CBF associated with reduction in OEF was seen in vulnerable regions, but did not persist at 24 h.

CONCLUSIONS: We demonstrated that this novel agent can improve regional CBF and may improve oxygen supply-demand balance. Clinical studies (likely with repeat dosing) are required to evaluate whether this effect can prevent DCI or cerebral infarction.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Dhar R, Misra H, Diringer MN, et al. SANGUINATE™ (PEGylated Carboxyhemoglobin Bovine) Improves Cerebral Blood Flow to Vulnerable Brain Regions at Risk of Delayed Cerebral Ischemia After Subarachnoid Hemorrhage. Neurocrit Care. 2017. PMID: 28639001. doi:10.1007/s12028-017-0418-3

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。